Aroa Biosurgery Ltd ARX
ASX · Australia · Health Technology
AUD 0.4900-0.04 (-6.67%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced the peer-reviewed publication of interim results from its ongoing MASTRR Registry, reporting low infection rates and no adverse events definitely related to Myriad products.
As the Australian market holds steady, waiting for crucial inflation data, investors are keeping a close eye on potential opportunities amidst global economic shifts. Penny stocks, a term that may seem outdated but remains relevant, represent smaller or newer companies with potential for growth and value. By focusing on those with strong financials and clear growth trajectories, investors can uncover promising opportunities in this unique segment of the market.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.